CoChat

Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Neumiller, Joshua J., Wood, Lindy, Campbell, R. Keith · 2010 · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Cited by 150

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Type 2 diabetes mellitus traditionally has been characterized by insulin resistance and β‐cell dysfunction, leading to hyperglycemia and eventual micro‐ and macrovascular complications. Dipeptidyl peptidase‐4 (DPP‐4) inhibitors are a relatively new class of drugs available for the management of type 2 diabetes. In order to provide a comprehensive evaluation and comparison of the pharmacology, pharmacokinetics, efficacy, and safety of the DPP‐4 inhibitors—sitagliptin, vildagliptin, saxagliptin, and alogliptin—in the treatment of type 2 diabetes, we conducted a MEDLINE search (1966–July 2009) for pertinent English‐language articles. Abstracts of the annual meetings of the American Diabetes Association and European Association for the Study of Diabetes from 2005–2009 were also searched. As a drug class, the DPP‐4 inhibitors have become widely accepted in clinical practice because of their low risk of hypoglycemia, favorable adverse‐effect profile, and once‐daily dosing. They are weight neutral (do not cause weight gain or loss) and appear to decrease β‐cell apoptosis and increase β‐cell survival. Because clinical studies directly comparing agents from this class have not, to our knowledge, been conducted, making comparisons in terms of efficacy and safety will become difficult for clinicians as more agents become available. Based on information from preclinical, clinical, and postmarketing data, there does not appear to be a compelling advantage of one DPP‐4 inhibitor over another in terms of efficacy, safety, or ease of clinical use. Although theoretical advantages exist for agents with a higher specificity for DPP‐4 inhibition versus inhibition of other isoenzymes associated with toxicity comparative studies and/or increased clinical experience with this class of drug will determine the clinical advantages, if any, of one agent over another.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1592/phco.30.5.463

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 150

Metadata

Authors
Neumiller, J. J., Wood, L., & Campbell, R. K.
Venue
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Publisher
Wiley
Published
2010-05
Volume
30
Issue
5
Pages
463-484
ISSN
  • 0277-0008 (ISSN-L)
  • 1875-9114
OpenAlex
W1991969856
Cited by
150
References
20
FWCI
14.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1592/phco.30.5.463
The paper
Neumiller, J. J., Wood, L., & Campbell, R. K. (2010). Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.30.5.463

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.